loading page

Real-world high adherence to Hepatitis B antiviral treatment practice guidelines in Israel
  • +1
  • Yana Davidov,
  • Fadi Abu Baker,
  • Ariel Israel,
  • Ziv Ben Ari
Yana Davidov
Sheba Medical Center

Corresponding Author:[email protected]

Author Profile
Fadi Abu Baker
Hillel Yaffe Medical Center
Author Profile
Ariel Israel
Leumit Health Care Services
Author Profile
Ziv Ben Ari
Sheba Medical Center
Author Profile

Abstract

Rationale, aims and objectives: Epidemiologic data regarding chronic hepatitis B virus infections in Israel is limited as large population-based study have not been performed. This work aimed to evaluate the current characteristics of hepatitis B infection among Israeli adults, and to evaluate adherence to European Association for the Study of the Liver practice guidelines for antiviral treatment. Methods: Clinical and demographic data of HBsAg-positive patients registered in the Leumit-Health-Service database (one of the four major health maintenance organizations in Israel) between 2000-2019 were retrieved. Patients were compared according to eligibility to antiviral treatment and type of nucleos(t)ide analogue (NA) treatment. Results: In total, 1216 patients had documented HBsAg positivity (males 58.6%, mean age 40.2±14.2 years), 90.6% of whom were HBeAg negative. Antiviral therapy eligibility was met by 37% of patients, among whom 89% received antiviral therapy. Antiviral therapies include NA with a high barrier to resistance (HBR) (64.5%) (entecavir 36.3% and tenofovir 28.2%) and NA with a low barrier to resistance (LBR) (35.5%) (adefovir 1.7% and lamivudine 33.8%). Compared to patients who received LBR NA, patients receiving HBR NA had shorter treatment (68.7±50vs.161.5±42.6 months, p<0.0001) and follow-up duration (125±68vs.188±48 months, p<0.0001); at the end of follow-up, ALT levels and APRI score were higher among patients on LBR NA compared to patients on HBR NA. Conclusion: Most patients received antiviral treatment according to the international practice guidelines. However, one-third of them were treated with a less potent NA, probably due to their lower cost. These findings should encourage the optimization of HBV care and full compliance with the professional practice guidelines recommendations.